Macrophage pyroptosis

Macrophage pyroptosis is **not a single molecular target** but rather refers to a form of programmed cell death occurring in macrophages that is highly inflammatory. This process involves the activation of inflammasomes—multi-protein complexes such as NLRP3—which then activate inflammatory caspases like caspase‑1/4/5/11. These caspases cleave gasdermin D (GSDMD), whose N-terminal fragment forms pores in the plasma membrane. The result is cell swelling, rupture, and release of cellular contents including pro-inflammatory cytokines such as interleukin 1 beta (IL‑1β) and interleukin 18 (IL‑18), along with other damage-associated molecular patterns like HMGB1 and ATP. This amplifies local inflammation by recruiting additional immune cells[3][2][1]. Pyroptosis can be triggered via canonical pathways involving pattern recognition receptors sensing pathogens or danger signals leading to inflammasome assembly and caspase activation; non-canonical pathways involve direct sensing of intracellular LPS by caspase‑4/5/11; alternative routes include chemotherapeutic drug-induced cleavage events activating other gasdermin family members[3][1]. Because "macrophage pyroptosis" describes a **cellular event** rather than an individual protein/receptor/enzyme/transporter/etc., it should not be considered a canonical therapeutic target itself. Instead, its underlying mediators—such as NLRP3 inflammasome components, specific caspases, or gasdermins—are more appropriate molecular targets for therapeutic intervention[2][3].

Other names

Pyroptosis in macrophagesInflammatory cell death in macrophages